The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
JOENJA Ballia Holdings Pty Ltd
Product name
JOENJA
Sponsor
Accepted date
Aug-2023
Active ingredients
leniolisib phosphate
Proposed indication
For the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents.
Application type
A (new medicine)
Publication date
Aug-2023
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.